Your browser doesn't support javascript.
loading
Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48].
Hernando, Jorge; Roca-Herrera, Maria; García-Álvarez, Alejandro; Raymond, Eric; Ruszniewski, Philippe; Kulke, Matthew H; Grande, Enrique; Carbonero, Rocío García; Castellano, Daniel; Salazar, Ramón; Ibrahim, Toni; Teule, Alex; Alonso, Vicente; Fazio, Nicola; Valle, Juan W; Tafuto, Salvatore; Carmona, Ana; Navarro, Victor; Capdevila, Jaume.
Afiliación
  • Hernando J; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: jhernando@vhio.net.
  • Roca-Herrera M; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • García-Álvarez A; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Raymond E; Department of Oncology, Paris Saint-Joseph Hospital, 185 rue Raymond Losserand, 75014 Paris, France.
  • Ruszniewski P; Université Paris Cité, and Dept of Pancreatology-Digestive Oncology, Beaujon Hospital, Clichy, France.
  • Kulke MH; Hematology/Oncology Unit, Boston Medical Center, USA.
  • Grande E; Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Carbonero RG; Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Universidad Complutense de Madrid (UCM), CNIO, CIBERONC, Madrid, Spain.
  • Castellano D; Oncología Médica, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Salazar R; Medical Oncology Department - Institut Català d'Oncologia, Oncobell Program-IDIBELL, University of Barcelona, CIBERONC, Barcelona, Spain.
  • Ibrahim T; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Teule A; Department of Medical Oncology, Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain.
  • Alonso V; Oncology Department, Hospital Universitario Miguel Servet, Instituto Investigación Sanitaria Aragón, CIBERONC, Zaragoza, Spain.
  • Fazio N; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy.
  • Valle JW; Division of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Tafuto S; Sarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S., Fondazione "G.Pascale", Naples, Italy.
  • Carmona A; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Navarro V; Oncology Data Science Group (ODysSey), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Capdevila J; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Eur J Cancer ; 203: 114061, 2024 May.
Article en En | MEDLINE | ID: mdl-38609739
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Eur J Cancer Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Eur J Cancer Año: 2024 Tipo del documento: Article